Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QTTB | 51.95% | $39.95M | -68.88% | 0.00% |
ANAB | 41.43% | $482.29M | -32.47% | 0.00% |
ENTA | 40.62% | $111.27M | -55.17% | 0.00% |
PLAY | 40.57% | $926.76M | -50.44% | 0.00% |
CARM | 34.14% | $18.40M | -80.76% | 0.00% |
GRAL | 33.13% | $585.33M | +2.47% | 0.00% |
IBRX | 31.09% | $2.15B | -18.33% | 0.00% |
AQB | 31.06% | $3.07M | -58.39% | 0.00% |
ARVN | 30.62% | $1.24B | -50.44% | 0.00% |
XYL | 28.87% | $29.07B | +6.96% | 1.20% |
VRA | 28.76% | $104.81M | -49.26% | 0.00% |
IDYA | 28.46% | $1.92B | -45.94% | 0.00% |
BLCO | 27.60% | $6.11B | +18.99% | 0.00% |
SNDX | 27.49% | $1.12B | -36.75% | 0.00% |
UBER | 27.18% | $141.80B | +3.42% | 0.00% |
PDSB | 26.96% | $54.24M | -67.78% | 0.00% |
VEEV | 26.85% | $35.16B | +4.56% | 0.00% |
NTLA | 25.93% | $967.57M | -62.82% | 0.00% |
CYRX | 25.68% | $370.73M | -48.10% | 0.00% |
CRSP | 25.55% | $3.46B | -34.62% | 0.00% |
SeekingAlpha
Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead, covering key events like earnings reports, IPOs, and Fed meetings.
Yahoo
On Tuesday, Cellectar Biosciences, Inc. (NASDAQ:CLRB) unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer. Due to recent communications with the FDA regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company has decided to pursue strategic options for the further development and commercialization of this product candidate. Also Read
Finnhub
By Josh Beckerman Cellectar Biosciences shares fell sharply after it revised its plans for its cancer-focused phospholipid ether drug conjugate platform and said it would cut 60% of its...
Finnhub
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring Evaluating strategic options for iopofosine I 131 a late-stage...
Yahoo
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the
SeekingAlpha
Stay informed on key market events with Seeking Alpha's Wall Street Week Ahead.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FENG | -<0.01% | $13.64M | +68.24% | 0.00% |
HPK | -0.04% | $1.87B | +11.48% | 1.08% |
INTA | -0.06% | $5.22B | +53.26% | 0.00% |
ALAB | -0.06% | $21.14B | +270.28% | 0.00% |
BOC | 0.07% | $463.71M | -0.81% | 0.00% |
ATUS | 0.10% | $1.27B | +25.45% | 0.00% |
LAUR | 0.11% | $2.82B | +47.44% | 0.00% |
BCS | -0.11% | $51.34B | +93.75% | 2.90% |
CRGY | 0.11% | $3.11B | +51.64% | 2.90% |
MKC | -0.13% | $19.67B | +12.73% | 2.32% |
WIX | -0.14% | $13.40B | +89.45% | 0.00% |
BCAN | -0.15% | $40.37M | -99.47% | 0.00% |
PLMR | -0.26% | $2.92B | +76.59% | 0.00% |
CPSH | -0.27% | $26.29M | -21.65% | 0.00% |
SPT | -0.28% | $1.87B | -46.22% | 0.00% |
PJT | -0.28% | $3.77B | +62.25% | 0.62% |
TWLO | 0.30% | $17.17B | +52.59% | 0.00% |
CIG.C | 0.33% | $2.25B | +6.01% | 0.00% |
BNED | -0.33% | $337.19M | -86.99% | 0.00% |
IBKR | 0.34% | $20.70B | +111.71% | 0.44% |
Current Value
$0.251 Year Return
Current Value
$0.251 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PDCO | -48.82% | $2.73B | +2.45% | 3.36% |
EQC | -23.71% | $180.32M | +25.41% | 0.00% |
XGN | -19.12% | $70.37M | +101.52% | 0.00% |
FIGS | -14.70% | $1.01B | +0.34% | 0.00% |
SFIX | -13.74% | $640.56M | +56.35% | 0.00% |
LFVN | -13.26% | $317.01M | +328.98% | 0.61% |
CRK | -12.75% | $6.25B | +167.46% | 0.00% |
GOOG | -8.82% | $2.42T | +33.51% | 0.30% |
GOOGL | -8.63% | $2.40T | +33.90% | 0.30% |
SPWH | -8.28% | $82.37M | -43.34% | 0.00% |
EQT | -8.21% | $31.60B | +49.90% | 1.20% |
SEI | -8.10% | $1.16B | +350.65% | 1.55% |
LGTY | -8.00% | $371.15M | -5.33% | 4.95% |
AU | -7.33% | $13.74B | +68.15% | 0.79% |
AXS | -7.27% | $7.55B | +62.52% | 1.94% |
RPTX | -7.23% | $54.41M | -79.15% | 0.00% |
ET | -6.89% | $69.47B | +47.14% | 6.23% |
RDY | -6.72% | $12.41B | +9.74% | 3.21% |
GL | -6.62% | $9.93B | -2.88% | 0.81% |
LOMA | -6.52% | $1.28B | +56.31% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 38.39% | $274.39M | 0% |
QQA | 35.25% | $147.14M | 0% |
GNOM | 30.77% | $67.06M | 0.5% |
IBB | 30.19% | $6.26B | 0.45% |
XBI | 29.93% | $6.10B | 0.35% |
ARKG | 29.17% | $1.10B | 0.75% |
IYT | 28.69% | $769.73M | 0.39% |
PTH | 28.27% | $119.40M | 0.6% |
PBE | 28.10% | $250.32M | 0.58% |
FHLC | 28.10% | $2.69B | 0.084% |
VHT | 27.82% | $16.63B | 0.1% |
PINK | 27.31% | $139.66M | 0.5% |
IHF | 26.87% | $676.28M | 0.4% |
XLV | 26.38% | $37.46B | 0.09% |
XPH | 26.37% | $165.13M | 0.35% |
IYH | 26.18% | $3.13B | 0.39% |
RSPH | 25.99% | $833.06M | 0.4% |
IWC | 25.96% | $960.97M | 0.6% |
PBW | 24.38% | $306.60M | 0.65% |
BBH | 24.24% | $391.30M | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CTA | -12.71% | $555.39M | 0.76% |
TPMN | -12.43% | $34.33M | 0.65% |
UNG | -11.70% | $852.27M | 1.06% |
VIXY | -11.07% | $195.31M | 0.85% |
DBO | -10.19% | $219.60M | 0.77% |
GSG | -10.09% | $1.07B | 0.75% |
EQLS | -9.69% | $9.14M | 1% |
DBE | -9.57% | $51.45M | 0.77% |
PDBC | -9.11% | $4.49B | 0.59% |
GCC | -8.42% | $134.04M | 0.55% |
DBC | -8.22% | $1.38B | 0.87% |
UUP | -8.20% | $642.45M | 0.77% |
COMT | -7.50% | $722.55M | 0.48% |
TAIL | -7.33% | $65.49M | 0.59% |
FTGC | -7.21% | $2.40B | 1.02% |
BCI | -6.98% | $1.38B | 0.26% |
CANE | -6.85% | $12.21M | 0.29% |
USCI | -6.32% | $204.06M | 1.07% |
USDU | -6.16% | $397.27M | 0.5% |
TESL | -5.85% | $20.28M | 1.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ICLO | 0.01% | $301.85M | 0.2% |
HYEM | -0.22% | $395.57M | 0.4% |
CPER | -0.23% | $157.04M | 0.97% |
AGZD | 0.44% | $148.39M | 0.23% |
GOAU | -0.67% | $87.87M | 0.6% |
VRIG | 0.70% | $1.20B | 0.3% |
CSHI | -0.76% | $522.14M | 0.38% |
BTF | 0.89% | $37.42M | 1.24% |
ARGT | 1.04% | $1.08B | 0.59% |
HIGH | 1.08% | $245.77M | 0.52% |
EWZS | -1.12% | $107.05M | 0.6% |
FBY | 1.27% | $168.27M | 0.99% |
THTA | 1.32% | $36.93M | 0.49% |
ULST | 1.51% | $554.46M | 0.2% |
DBB | 1.54% | $110.86M | 0.77% |
DEFI | 1.70% | $15.95M | 0.94% |
GDXJ | 1.73% | $4.71B | 0.52% |
FLTR | 1.74% | $1.98B | 0.14% |
ARKB | 1.76% | $4.90B | 0.21% |
GDX | -1.77% | $13.47B | 0.51% |